Published in Circ Cardiovasc Genet on November 18, 2011
Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol (2013) 2.30
Clinical and genetic determinants of torsade de pointes risk. Circulation (2012) 1.67
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol (2014) 1.65
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Dysfunctional potassium channel subunit interaction as a novel mechanism of long QT syndrome. Heart Rhythm (2013) 1.39
Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res (2012) 1.25
Molecular and genetic basis of sudden cardiac death. J Clin Invest (2013) 1.23
Genetic testing for inherited cardiac disease. Nat Rev Cardiol (2013) 1.20
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One (2013) 1.04
Pharmacogenomics of adverse drug reactions. Genome Med (2013) 1.00
Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J (2012) 1.00
The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J (2014) 0.97
Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res (2015) 0.96
Systems biology and cardiac arrhythmias. Lancet (2012) 0.92
Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol (2015) 0.90
The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J (2015) 0.89
KCNE1 and KCNE3: The yin and yang of voltage-gated K(+) channel regulation. Gene (2015) 0.89
KCNE genetics and pharmacogenomics in cardiac arrhythmias: much ado about nothing? Expert Rev Clin Pharmacol (2013) 0.85
Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J (2013) 0.84
Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition. Physiol Rep (2013) 0.84
The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur Heart J (2012) 0.83
Predicting drug-induced QT prolongation and torsades de pointes. J Physiol (2016) 0.82
Congenital Long QT Syndrome: An Update and Present Perspective in Saudi Arabia. Front Pediatr (2013) 0.81
Evidence of heterogeneity by race/ethnicity in genetic determinants of QT interval. Epidemiology (2014) 0.81
Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention. Epilepsia (2016) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
The genetics of pro-arrhythmic adverse drug reactions. Br J Clin Pharmacol (2014) 0.80
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study. Pharmacogenet Genomics (2014) 0.78
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits. PLoS One (2014) 0.77
A non-synonymous single nucleotide polymorphism in an OPRM1 splice variant is associated with fentanyl-induced emesis in women undergoing minor gynaecological surgery. PLoS One (2012) 0.77
Genetic screening in acquired long QT syndrome? CAUTION: proceed carefully. Eur Heart J (2015) 0.77
Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update. Drug Saf (2015) 0.77
Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Can J Cardiol (2012) 0.77
A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk? Ther Adv Infect Dis (2014) 0.77
Easily configured real-time CPOE Pick Off Tool supporting focused clinical research and quality improvement. J Am Med Inform Assoc (2013) 0.76
Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study. Circulation (2017) 0.75
Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin (2016) 0.75
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev (2016) 0.75
Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports (2017) 0.75
Personalized medicine to treat arrhythmias. Curr Opin Pharmacol (2013) 0.75
A Bayesian approach to identify genes and gene-level SNP aggregates in a genetic analysis of cancer data. Stat Interface (2015) 0.75
GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOL study": Lack of common variants with large effect sizes. PLoS One (2017) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Inference of population structure using multilocus genotype data. Genetics (2000) 147.76
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
A haplotype map of the human genome. Nature (2005) 105.70
Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics (2003) 53.11
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 6.78
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
KORA--a research platform for population based health research. Gesundheitswesen (2005) 3.95
Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation (2005) 3.31
Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation (2005) 2.77
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. Circulation (2008) 2.34
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol (2009) 2.12
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm (2007) 1.93
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
When good drugs go bad. Nature (2007) 1.85
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 1.76
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Systems pharmacology of arrhythmias. Sci Signal (2010) 1.72
Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. Heart Rhythm (2010) 1.58
Common candidate gene variants are associated with QT interval duration in the general population. J Intern Med (2009) 1.35
Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol (2009) 1.33
Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res (2002) 1.14
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm (2005) 1.10
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur J Hum Genet (2007) 1.08
Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart (2010) 1.01
The perfect storm: defective calcium cycling in insulated fibers with reduced repolarization reserve. Circ Res (2007) 0.80
[Spike torsades with syncopal expression caused by hypokalemia]. Coeur Med Interne (1972) 0.78
Long Q-T syndrome precipitated by atropine and hypokalemia. Dev Pharmacol Ther (1983) 0.77
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation (2010) 19.30
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet (2008) 16.25
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
A common genetic variant is associated with adult and childhood obesity. Science (2006) 14.95
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Universal definition of myocardial infarction. Circulation (2007) 11.69
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics (2003) 9.91
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet (2012) 8.42
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07
The DNA sequence of the human X chromosome. Nature (2005) 6.97
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet (2005) 6.36
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardiol (2005) 5.99
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature (2003) 5.94
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med (2010) 5.32
Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet (2008) 5.23